CSPC PHARMA (01093) announced that its self-developed SYS 6010, a humanized monoclonal antibody-drug conjugate targeting EGFR, has been included again in China's National Medical Products Administration's Breakthrough Therapy Designation list. The intended indication is for monotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma who have failed prior platinum-containing chemotherapy and immunotherapy. Clinical studies for this indication have demonstrated breakthrough efficacy. Compared to existing standard treatments for recurrent esophageal cancer, SYS 6010 is expected to provide more significant clinical benefits with a favorable safety profile, showing clear clinical advantages. Currently, the group has officially initiated a Phase III confirmatory clinical study for this esophageal squamous cell carcinoma indication and is accelerating its progress. Concurrently, multiple Phase III clinical studies for other solid tumor indications are underway, including first-line treatment for non-small cell lung cancer, second-line treatment for non-small cell lung cancer, and second-line or later treatment for breast cancer. Previously, in January 2025, the product received Breakthrough Therapy Designation for the EGFR mutation-resistant non-small cell lung cancer indication. The inclusion of the esophageal squamous cell carcinoma indication in the Breakthrough Therapy list will help expedite the overall clinical development and regulatory review and approval process for its various solid tumor indications. This will facilitate the product's early market entry, providing a new and effective treatment option for patients with advanced tumors. It will also continuously enhance the group's pipeline in the oncology treatment field, consolidating and strengthening its differentiated R&D capabilities and market competitive advantages in the antibody-drug conjugate sector.
Comments